Psilocybin Without Psychotherapy: A Cart Without a Horse?
American Journal of Psychiatry January 1, 2024 Mitch Earleywine, Joseph de Leo, Dinesh Bhayana et al. 23 citations
No Summary
Bhavya Rajanna
Department of Medicine, Baystate Medical Center, Springfield, Massachusetts, USA.
2 papers in the library · 32 citations · publishing 2023-2024
Papers
Psychedelic Use Among Psychiatric Medication Prescribers: Effects on Well-Being, Depression, Anxiety, and Associations with Patterns of Use, Reported Harms, and Transformative Mental States.
Psychedelic medicine (New Rochelle, N.Y.) September 1, 2023 Zachary Herrmann, Adam W Levin, Steven P Cole et al. 9 citations
Among 228 healthcare providers who treat psychiatric disorders with medications and reported at least one lifetime psychedelic use, retrospective measures showed improvements in depression, anxiety, and well-being after psychedelic exposure. Suicidality decreased and resilience increased. A factor analysis indicated that a cluster of mystical, interpersonal, and personal experiences predicted these improvements. The preferred psychedelic agent did not affect outcomes, and frequency of use was not associated with outcomes, though effect sizes varied. Harm was reported by 13.2% (n = 30), consistent with general population rates. Pre-exposure alcohol use, aggressive impulses, and desire to die by suicide improved most often, while marijuana use most often worsened or did not change.